Quantcast
Last updated on April 17, 2014 at 13:47 EDT

Latest Eisai Co. Ltd. Stories

2014-03-31 04:20:57

WOODCLIFF LAKE, N.J., March 31, 2014 /PRNewswire/ -- Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license for DACOGEN(®) (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd., giving Otsuka full development and commercialization rights for the product in the former Eisai territories of the United States, Canada and Japan. Eisai will retain its rights for DACOGEN(®) in Mexico. In...

2014-03-20 12:32:40

JOINT RESEARCH PROJECT AWARDED GHIT FUND GRANT TOKYO, March 20, 2014 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai?") announced today that it has entered a collaboration with the Liverpool School of Tropical Medicine (Liverpool, United Kingdom, ?"LSTM?") and University of Liverpool (Liverpool, United Kingdom, ?"UoL") to jointly identify new drugs effective against lymphatic filariasis and onchocerciasis (river blindness), both major...

2014-03-11 12:29:05

LONDON, March 11, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Alzheimer's Disease Therapeutics and Diagnostics: World Market 2013-2023 Report DetailsAlzheimer's medicine - your guide to technologies, trends and revenuesWhere's treatment of Alzheimer's disease heading? Visiongain's new report gives you revenue predictions for those drugs and diagnostic tests from 2013, helping you stay ahead.There you find financial data, R&D trends,...

2014-03-10 08:30:23

Company Appoints New Executive Leaders WOODCLIFF LAKE, N.J., March 10, 2014 /PRNewswire/ -- Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the appointments of Yuji Matsue as chairman and chief executive officer and Shaji Procida as president and chief operating officer, effective April 1, 2014. Mr. Matsue and Ms. Procida succeed current President and CEO Lonnel Coats, who will be retiring from Eisai in June 2014 after 18 years. Over the next few months,...

2014-02-03 04:20:02

Tokyo, Feb 3, 2014 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.DC Bead contains hydrophilic microspheres made from cross-linked polyvinyl alcohol polymer. Developed by Biocompatibles UK Limited (Biocompatibles), a BTG International group company, as an intravascular embolization device, it is injected via catheter into targeted blood...

2014-01-22 12:23:39

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Pharmerging Markets 2012-2016TechNavio's analysts forecast the Pharmerging market to grow at a CAGR of 12.44 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in healthcare spending. The Pharmerging market has also been witnessing an increase in partnerships among vendors. However, the price pressure could pose a challenge to the...

2013-11-25 08:28:22

TOKYO, Nov. 25, 2013 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has become a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, a groundbreaking initiative that aims to speed up the discovery of essential new treatments for tuberculosis (TB). (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) Jointly launched in June 2012 through a collaborative agreement among seven...

2013-11-07 16:31:09

-- Collaboration to Focus on Global Commercialization and Development for Weight Management and Potential New Indications -- SAN DIEGO, Calif. and WOODCLIFF LAKE, N.J., Nov. 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the BELVIQ(®) (lorcaserin HCl) marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. along with its parent company Eisai...

2013-10-29 00:21:49

FIRST SHIPMENT TO BENEFIT MORE THAN 6 MILLION PEOPLE IN 4 ENDEMIC COUNTRIES WOODCLIFF LAKE, N.J., Oct. 28, 2013 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has begun the free supply of diethylcarbamazine citrate (DEC) 100 mg tablets produced at its Vizag Plant in India to the World Health Organization (WHO) in line with its commitment to help WHO in its global effort to eliminate lymphatic filariasis in...

2013-10-16 23:23:04

Reportbuyer.com just published a new market research report: Alzheimer’s Disease Therapeutics and Diagnostics: World Market 2013-2023. London (PRWEB) October 16, 2013 Alzheimer's medicine - your guide to technologies, trends and revenues Where's treatment of Alzheimer's disease heading? Visiongain's new report gives you revenue predictions for those drugs and diagnostic tests from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities,...